PAVmed Chairman & CEO Lishan Aklog, M.D. Named to Savoy’s 2022 Most Influential Black Executives in Corporate America
19 Juli 2022 - 2:25PM
Business Wire
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a
diversified commercial-stage medical technology company operating
in the medical device, diagnostics, and digital health sectors,
today announced that its Chairman & Chief Executive Officer
Lishan Aklog, M.D. was selected as one of the Most Influential
Black Executives in Corporate America in 2022 by Savoy, the leading
African American business and lifestyle magazine.
“I would like to thank L.P. Green II and his team at Savoy for
this honor,” said Dr. Aklog. “I am incredibly fortunate to lead a
growing team of the best and brightest, who all share a passion to
serve patients through technology. I am especially honored to be
mentioned among such an esteemed group of Black corporate leaders,
including pioneering figures who battled structural inequities and
biases to reach the pinnacle of corporate America, while serving as
an inspiration to me and so many others.”
“Savoy is proud to present the 2022 Most Influential Black
Executives in Corporate America. In this issue, we assembled an
elite representation of African American men and women who have
been recognized for their executive and business leadership in
national and global-leading corporations,” said L.P. Green, II,
Publisher of Savoy magazine. “These innovative trailblazers have
led efforts to foster growth for some of the country’s
highest-performing companies throughout and beyond the US
market.”
According to Savoy, the selection of the Most Influential Black
Executives in Corporate America begins by examining the landscape
of spheres of influence impacting Savoy’s readership. Over 500
prospective candidates in diverse fields were pre-screened by the
selection committee. The field of candidates was narrowed based
upon their exemplary record of accomplishments and influence while
working to better their community and inspire others.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its major subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD) is a commercial-stage cancer prevention medical
diagnostics company which markets the EsoGuard® Esophageal DNA Test
and EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal
precancer to prevent esophageal cancer deaths. Lucid operates its
own CLIA-certified, CAP-approved molecular diagnostic laboratory,
LucidDx Labs and a network of Lucid Test Centers. Another major
subsidiary, Veris Health Inc., is a digital health company focused
on enhanced personalized cancer care through remote patient
monitoring using implantable biologic sensors with wireless
communication along with a custom suite of connected external
devices. The product pipeline also includes the CarpX® Minimally
Invasive Device for Carpal Tunnel Syndrome, EsoCure™ Esophageal
Ablation Device with Caldus™ Technology, which complements EsoGuard
and EsoCheck, NextFlo™ Intravenous Infusion Set, PortIO™
Implantable Intraosseous Vascular Access Device, and other earlier
stage technologies. For more information on PAVmed, please visit
PAVmed.com and follow PAVmed on Twitter, LinkedIn, and YouTube. For
more information on Lucid, please visit LucidDx.com and follow
Lucid on Twitter, and LinkedIn. For detailed information on
EsoGuard, please visit EsoGuard.com and follow EsoGuard on Twitter,
Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s and Lucid’s management, are subject to
risks and uncertainties, which could cause actual results to differ
from the forward-looking statements. Risks and uncertainties that
may cause such differences include, among other things, volatility
in the price of PAVmed’s and Lucid’s common stock; PAVmed’s Series
W and Series Z warrants; general economic and market conditions;
the uncertainties inherent in research and development, including
the cost and time required to advance PAVmed’s and Lucid’s products
to regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed’s and Lucid’s
clinical and preclinical studies; whether and when PAVmed’s and
Lucid’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s and Lucid’s products once cleared and
commercialized; PAVmed’s and Lucid’s ability to raise additional
funding as needed; and other competitive developments. In addition,
PAVmed and Lucid have been monitoring the COVID-19 pandemic and the
pandemic’s impact on PAVmed’s and Lucid’s businesses. PAVmed and
Lucid expect the significance of the COVID-19 pandemic, including
the extent of its effect on its financial and operational results,
to be dictated by, among other things, the success of efforts to
contain the pandemic and the impact of such efforts on PAVmed’s and
Lucid’s businesses. These factors are difficult or impossible to
predict accurately and many of them are beyond PAVmed’s and Lucid’s
control. In addition, new risks and uncertainties may arise from
time to time and are difficult to predict. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s and Lucid’s future operations, see Part I,
Item IA, “Risk Factors,” in PAVmed’s and Lucid’s most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Report on Form 10-Q filed by PAVmed or
Lucid, as applicable, after its most recent Annual Report and
Lucid’s Registration Statement No. 333-259721 filed with the
Securities and Exchange Commission. PAVmed and Lucid disclaim any
intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in its expectations
or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that
actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220719005025/en/
Investors Adrian K. Miller PAVmed
Inc. AKM@PAVmed.com Media Shani Lewis
LaVoieHealthScience (609) 516-5761
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Mai 2023 bis Mai 2024